메뉴 건너뛰기




Volumn 31, Issue 16, 2013, Pages 1947-1953

Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2–overexpressing metastatic breast cancer

(17)  Guan, Zhongzhen a   Xu, Binghe b   Desilvio, Michelle L i   Shen, Zhenzhou f   Arpornwirat, Wichit j   Tong, Zhongsheng h   Lorvidhaya, Vicharn k   Jiang, Zefei c   Yang, Junlan d   Makhson, Anatoly l   Leung, Wai Lim m   Russo, Mark W i   Newstat, Beth i   Wang, Li g   Chen, George e   Oliva, Cristina n   Gomez, Henry o  

g Eli Lilly *  (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LOPERAMIDE; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

EID: 84880452171     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.5241     Document Type: Article
Times cited : (128)

References (23)
  • 1
    • 73149115341 scopus 로고    scopus 로고
    • Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
    • Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 5538-5546
    • Johnston, S.1    Pippen, J.2    Pivot, X.3
  • 2
    • 33749074278 scopus 로고    scopus 로고
    • Erbb receptors and their ligands in the breast
    • Zahnow CA: ErbB receptors and their ligands in the breast. Expert Rev Mol Med 8:1-21, 2006
    • (2006) Expert Rev Mol Med , vol.8 , pp. 1-21
    • Zahnow, C.A.1
  • 3
    • 34547676475 scopus 로고    scopus 로고
    • Erbb receptors: From oncogenes to targeted cancer therapies
    • Zhang H, Berezov A, Wang Q, et al: ErbB receptors: From oncogenes to targeted cancer therapies. J Clin Invest 117:2051-2058, 2007
    • (2007) J Clin Invest , vol.117 , pp. 2051-2058
    • Zhang, H.1    Berezov, A.2    Wang, Q.3
  • 4
    • 33748192481 scopus 로고    scopus 로고
    • The erbb2 signaling network as a target for breast cancer therapy
    • Badache A, Goncalves A: The ErbB2 signaling network as a target for breast cancer therapy. J Mammary Gland Biol Neoplasia 11:13-25, 2006
    • (2006) J Mammary Gland Biol Neoplasia , vol.11 , pp. 13-25
    • Badache, A.1    Goncalves, A.2
  • 5
    • 0024337144 scopus 로고
    • Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer
    • Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
    • (1989) Science , vol.244 , pp. 707-712
    • Slamon, D.J.1    Godolphin, W.2    Jones, L.A.3
  • 6
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the her-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 7
    • 0036467826 scopus 로고    scopus 로고
    • Efficacy and safety of trastuzumab as a single agent in first-line treatment of her2-overexpressing metastatic breast cancer
    • Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
    • (2002) J Clin Oncol , vol.20 , pp. 719-726
    • Vogel, C.L.1    Cobleigh, M.A.2    Tripathy, D.3
  • 8
    • 46449113024 scopus 로고    scopus 로고
    • Efficacy and safety of lapatinib as first-line therapy for erbb2-amplified locally advanced or metastatic breast cancer
    • Gomez HL, Doval DC, Chavez MA, et al: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999-3005, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 2999-3005
    • Gomez, H.L.1    Doval, D.C.2    Chavez, M.A.3
  • 9
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses Her2
    • Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 10
    • 0036534121 scopus 로고    scopus 로고
    • Phase ii study of weekly docetaxel and trastuzumab for patients with her-2-overexpressing metastatic breast cancer
    • Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808, 2002
    • (2002) J Clin Oncol , vol.20 , pp. 1800-1808
    • Esteva, F.J.1    Valero, V.2    Booser, D.3
  • 11
    • 78349268795 scopus 로고    scopus 로고
    • A single-arm phase ii trial of first-line paclitaxel in combination with lapatinib in her2-overexpressing metastatic breast cancer
    • Jagiello-Gruszfeld A, Tjulandin S, Dobrovolskaya N, et al: A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. Oncology 79:129-135, 2010
    • (2010) Oncology , vol.79 , pp. 129-135
    • Jagiello-Gruszfeld, A.1    Tjulandin, S.2    Dobrovolskaya, N.3
  • 12
    • 57149096463 scopus 로고    scopus 로고
    • Phase iii, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
    • Di Leo A, Gomez HL, Aziz Z, et al: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544-5552, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 5544-5552
    • Di Leo, A.1    Gomez, H.L.2    Aziz, Z.3
  • 13
    • 33847147996 scopus 로고    scopus 로고
    • The combination of letrozole and trastuzumab as first or second-line biologic therapy produces durable responses in a subset of her2 positive and er positive advanced breast cancers
    • Marcom PK, Isaacs C, Harris L, et al: The combination of letrozole and trastuzumab as first or second-line biologic therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102:43-49, 2007
    • (2007) Breast Cancer Res Treat , vol.102 , pp. 43-49
    • Marcom, P.K.1    Isaacs, C.2    Harris, L.3
  • 14
    • 77949884661 scopus 로고    scopus 로고
    • Randomized study of lapatinib alone or in combination with trastuzumab in women with erbb2-positive, trastuzumab-refractory metastatic breast cancer
    • Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 1124-1130
    • Blackwell, K.L.1    Burstein, H.J.2    Storniolo, A.M.3
  • 15
    • 22344446208 scopus 로고    scopus 로고
    • Randomized phase ii trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The m77001 study group
    • Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 4265-4274
    • Marty, M.1    Cognetti, F.2    Maraninchi, D.3
  • 16
    • 84862914692 scopus 로고    scopus 로고
    • Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
    • Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
    • (2012) N Engl J Med , vol.366 , pp. 109-119
    • Baselga, J.1    Cortés, J.2    Kim, S.B.3
  • 17
    • 84866536687 scopus 로고    scopus 로고
    • Open-label phase iii randomized controlled trial comparing taxane-based chemotherapy (tax) with lapatinib (l) or trastuzumab (t) as first-line therapy for women with her2 metastatic breast cancer: Interim analysis (ia) of ncic ctg ma.31/gsk egf 108919
    • Gelmon KA, Boyle F, Kaufman B, et al: Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2 metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 30, 2012 (suppl; abstr LBA671)
    • (2012) J Clin Oncol , vol.30
    • Gelmon, K.A.1    Boyle, F.2    Kaufman, B.3
  • 20
    • 84857236823 scopus 로고    scopus 로고
    • Lapatinib with trastuzumab for her2-positive early breast cancer (neoaltto): A randomised, open-label, multicentre, phase 3 trial
    • Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-640, 2012
    • (2012) Lancet , vol.379 , pp. 633-640
    • Baselga, J.1    Bradbury, I.2    Eidtmann, H.3
  • 21
    • 85022342264 scopus 로고    scopus 로고
    • Correlation of clinical and molecular findings with pathologic response to preoperative lapatinib and trastuzumab, separately or in combination, prior to neoadjuvant chemotherapy for her2-positive breast cancer
    • Holmes FA, Espina VA, Liotta LA, et al: Correlation of clinical and molecular findings with pathologic response to preoperative lapatinib and trastuzumab, separately or in combination, prior to neoadjuvant chemotherapy for HER2-positive breast cancer. Presented at San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011
    • San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011
    • Holmes, F.A.1    Espina, V.A.2    Liotta, L.A.3
  • 22
    • 84864018421 scopus 로고    scopus 로고
    • Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase ii cher-lob study
    • Guarneri V, Frassoldati A, Bottini A, et al: Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study. J Clin Oncol 30:1989-1995, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 1989-1995
    • Guarneri, V.1    Frassoldati, A.2    Bottini, A.3
  • 23
    • 84856444501 scopus 로고    scopus 로고
    • Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (gepar-quinto, gbg 44): A randomised phase 3 trial
    • Untch M, Loibl S, Bischoff J, et al: Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (Gepar-Quinto, GBG 44): A randomised phase 3 trial. Lancet Oncol 13:135-144, 2012
    • (2012) Lancet Oncol , vol.13 , pp. 135-144
    • Untch, M.1    Loibl, S.2    Bischoff, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.